Thompson Davis & CO. Inc. Sells 7,244 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Thompson Davis & CO. Inc. decreased its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 33.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,600 shares of the company's stock after selling 7,244 shares during the period. Thompson Davis & CO. Inc. owned approximately 0.05% of GeneDx worth $620,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in WGS. Acadian Asset Management LLC bought a new stake in shares of GeneDx during the 2nd quarter worth about $34,000. nVerses Capital LLC acquired a new stake in GeneDx in the second quarter worth approximately $50,000. CWM LLC bought a new position in GeneDx during the 3rd quarter valued at $89,000. SG Americas Securities LLC acquired a new position in shares of GeneDx during the 3rd quarter valued at $198,000. Finally, Palumbo Wealth Management LLC acquired a new position in shares of GeneDx during the 3rd quarter valued at $287,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of research analyst reports. Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 30th. Craig Hallum raised their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. TD Cowen upped their price target on GeneDx from $46.00 to $50.00 and gave the company a "buy" rating in a report on Wednesday, July 31st. BTIG Research raised their price objective on GeneDx from $35.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, July 31st. Finally, The Goldman Sachs Group boosted their target price on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, GeneDx presently has an average rating of "Moderate Buy" and a consensus target price of $59.33.

GeneDx Stock Down 1.4 %

Shares of WGS traded down $0.97 during mid-day trading on Wednesday, reaching $70.07. The company's stock had a trading volume of 148,766 shares, compared to its average volume of 449,623. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -22.84 and a beta of 2.11. The business has a fifty day moving average of $57.43 and a 200 day moving average of $38.69. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 1 year low of $1.29 and a 1 year high of $89.11.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million for the quarter, compared to analysts' expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business's revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.82) EPS. As a group, analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Insider Buying and Selling at GeneDx

In related news, major shareholder School Of Medicine At Mo Icahn sold 865,800 shares of the stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $75.00, for a total value of $64,935,000.00. Following the transaction, the insider now owns 2,866,833 shares in the company, valued at approximately $215,012,475. This represents a 23.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Katherine Stueland sold 3,639 shares of GeneDx stock in a transaction on Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87. Following the completion of the sale, the chief executive officer now directly owns 95,457 shares of the company's stock, valued at approximately $3,181,581.81. The trade was a 3.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,065,580 shares of company stock worth $78,848,138. 27.30% of the stock is currently owned by company insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.